-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
OBJECTIVE: Patients with autoimmune inflammatory rheumatic disease treated with rituximab (RTX) were at higher risk of poor prognosis from COVID-19 infection and significantly impaired humoral immune responses against SARS-CoV-2 vacci.
The complex relationship between antigen-specific B cells and T cells and the level of B cell repopulation required to achieve an anti-vaccine response remains largely unkno.
RESULTS: Following SARS-CoV-2 vaccination, RTX-treated patients appeared to require at least 10 B cells (4% lymphocytes) per microliter of peripheral circulation to seroconvert to anti-Spike S1 I.
Following SARS-CoV-2 vaccination, RTX-treated patients appear to require at least 10 B cells (4% lymphocytes) per microliter in peripheral circulation to seroconvert to anti-Spike S1 I.
In RTX-treated patients, at least 10 B cells per microliter in the peripheral circulation are a candidate biomarker with a high likelihood of appropriate cellular and humoral responses following SARS-CoV-2 vaccinati.
leave a message here